ARTICLE | Company News
CVTX receives milestone
April 10, 2000 7:00 AM UTC
CV Therapeutics received a $6.5 million milestone from Biogen (BGEN) triggered by the completion in February of a Phase II trial of CVTX's CVT-124 adenosine A1 receptor antagonist to treat congestive ...